Bristol Myers: new data in schizophrenia

(CercleFinance.com) - Bristol Myers Squibb today announced that new clinical research and HEOR data from its neuropsychiatry portfolio evaluating COBENFY (xanomeline and trospium chloride) in adult schizophrenia will be presented at Psych Congress 2024, to be held from 29 October to 2 November in Boston, Massachusetts.


As we continue to strengthen our neuropsychiatry portfolio, we remain committed to developing and delivering differentiated options for patients.

Research to be presented at the meeting continues to demonstrate COBENFY as a differentiated treatment option for adults with schizophrenia.

Building on the momentum of COBENFY's recent approval by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults, we are pleased to share at Psych Congress additional data from the EMERGENT clinical trial program that highlight COBENFY's differentiated clinical profile, including efficacy, safety and patient-reported outcomes for adults with schizophrenia who participated in our long-term clinical trials, Bristol Myers Squibb said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.